Table 2 Adverse events leading to treatment discontinuation. Seventy patients (6.6%) discontinued galcanezumab due to 105 different adverse events
Adverse event | N (%) |
|---|---|
Dizziness | 19 (1.8) |
Constipation | 13 (1.2) |
Vertigo | 12 (1.1) |
Localized cutaneous rash | 9 (0.8) |
Injection site pain | 9 (0.8) |
Generalized cutaneous rash | 7 (0.6) |
Asthenia | 5 (0.5) |
Arterial hypotension | 3 (0.3) |
Drowsiness | 3 (0.3) |
Confusion | 3 (0.3) |
Diarrhea | 3 (0.3) |
Nausea | 3 (0.3) |
Paresthesia | 3 (0.3) |
Generalized pain | 3 (0.3) |
Anxiety | 2 (0.2) |
Increased weight | 2 (0,2) |
Anorexia | 1 (0.1) |
Tinnitus | 1 (0.1) |
Blurred vission | 1 (0.1) |
Abdominal pain | 1 (0.1) |
Blood pressure instability | 1 (0.1) |
Headache worsening | 1 (0.1) |